Lataa...
Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
BACKGROUND: Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma (advRCC) based on significant clinical benefits. METHODS: Patients with advRCC and multiple poor-prognostic factors were randomly assigned to receive 25 mg intravenous temsirolimus...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2869160/ https://ncbi.nlm.nih.gov/pubmed/20461090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605647 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|